Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Will PC et al. | Platelet activating factor as a proinflammatory mediator in acetic-induced colitis in the rat. | 1991 | Agents Actions | pmid:1793026 |
Vincent D et al. | Dissociation between LPS-induced bronchial hyperreactivity and airway edema in the guinea-pig. | 1991 | Agents Actions | pmid:1793031 |
Adolfs MJ et al. | PAF-acether modifies human peritoneal macrophage cAMP levels in a biphasic fashion. | 1989 | Agents Actions | pmid:2540635 |
Neumann M and Kownatzki E | The effect of adherence on the generation of reactive oxygen species by human neutrophilic granulocytes. | 1989 | Agents Actions | pmid:2540640 |
Ramesha CS et al. | Identification and quantitation of PAF from psoriatic scales. | 1987 | Agents Actions | pmid:3687590 |
Friedlander G et al. | Renal effects of platelet-activating factor in the rat. | 1987 | Agents Actions | pmid:3687594 |
Taira M et al. | Lack of involvement of leukotriene and platelet activating factor in passive cutaneous anaphylaxis in rats. | 1988 | Agents Actions | pmid:3407549 |
Pirotzky E et al. | Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. | 1985 | Agents Actions | pmid:4003192 |
Page CP et al. | Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. | 1985 | Agents Actions | pmid:4003195 |
Page CP et al. | Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. | 1985 | Agents Actions | pmid:4003196 |
Northover AM | In vitro effects of PAF on venous endothelial cell actin disposition. | 1992 | Agents Actions | pmid:1509977 |
Northover AM and Northover BJ | Lectin-induced increase in microvascular permeability to colloidal carbon in vitro may involve protein kinase C activation. | 1994 | Agents Actions | pmid:7942320 |
Tubaro E et al. | In vitro and in vivo impact of a new glycosphingolipid on neutrophils. | 1994 | Agents Actions | pmid:7879694 |
Canale P et al. | TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. | 1994 | Agents Actions | pmid:7879698 |
Perret BA et al. | Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. | 1981 | Agents Actions | pmid:6803540 |
Lecrubier C et al. | Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. | 1983 | Agents Actions | pmid:6858789 |
Heller R et al. | S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. | 1993 | Agents Actions | pmid:7517616 |
Czarnetzki BM and Benveniste J | Effect of synthetic PAF-acether on human neutrophil function. | 1981 | Agents Actions | pmid:7041568 |
Camussi G et al. | Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). | 1981 | Agents Actions | pmid:7041569 |
de Bernardis E et al. | Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. | 1994 | Agents Actions | pmid:7847181 |